BI 764198: meta-analysis of COVID-19 studies

All studies Mortality Serious outcomes Recovery RCTs RCT mortality Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−117%

Mortality (1)−117%

RCTs (1)−117%

Late (1)−117%

00.511.5+

← BI 764198
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

BI 764198 COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Ware (DB RCT)−117%2.17 · 0.80–5.88death11/655/64

Late treatment−117%2.17 · 0.80–5.8811/655/64117% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.13

All studies−117%2.17 · 0.80–5.8811/655/64117% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1300.511.52+

Rotate screen for more detailsIncrease width for more details

← BI 764198
reduces riskBI 764198
increases risk →

c19early.org

October 2026

BI 764198 COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Ware (DB RCT)−117%2.17 · 0.80–5.8811/655/64

Late treatment−117%2.17 · 0.80–5.8811/655/64117% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.13

All studies−117%2.17 · 0.80–5.8811/655/64117% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1300.511.52+

Rotate screen for more detailsIncrease width for more details

← BI 764198
reduces riskBI 764198
increases risk →

c19early.org

October 2026

BI 764198 COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Ware (DB RCT)−117%2.17 · 0.80–5.88death11/655/64

Late treatment−117%2.17 · 0.80–5.8811/655/64117% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.13

All studies−117%2.17 · 0.80–5.8811/655/64117% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1300.511.52+

Rotate screen for more detailsIncrease width for more details

← BI 764198
reduces riskBI 764198
increases risk →

c19early.org

October 2026

BI 764198 COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Ware (DB RCT)−42%1.42 · 0.65–3.09no recov.13/659/64

Late treatment−42%1.42 · 0.65–3.0913/659/6442% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.38

All studies−42%1.42 · 0.65–3.0913/659/6442% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.3800.511.52+

Rotate screen for more detailsIncrease width for more details

← BI 764198
reduces riskBI 764198
increases risk →

c19early.org

October 2026

BI 764198 COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Ware (DB RCT)−117%2.17 · 0.80–5.88death11/655/64

Late treatment−117%2.17 · 0.80–5.8811/655/64117% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.13

All studies−117%2.17 · 0.80–5.8811/655/64117% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1300.511.52+

Rotate screen for more detailsIncrease width for more details

← BI 764198
reduces riskBI 764198
increases risk →

c19early.org

October 2026

BI 764198 COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Ware (DB RCT)−117%2.17 · 0.80–5.8811/655/64

Late treatment−117%2.17 · 0.80–5.8811/655/64117% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.13

All studies−117%2.17 · 0.80–5.8811/655/64117% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1300.511.52+

Rotate screen for more detailsIncrease width for more details

← BI 764198
reduces riskBI 764198
increases risk →

c19early.org

October 2026

BI 764198 COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Ware (DB RCT)−117%2.17 · 0.80–5.88death11/655/64

Late treatment−117%2.17 · 0.80–5.8811/655/64117% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.13

All studies−117%2.17 · 0.80–5.8811/655/64117% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1300.511.52+

Rotate screen for more detailsIncrease width for more details

← BI 764198
reduces riskBI 764198
increases risk →

c19early.org

October 2026

BI 764198 COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Ware (DB RCT)−117%2.17 · 0.80–5.88death11/655/64 Ware (DB RCT)−97%1.97 · 0.71–5.44death10/655/64 Ware (DB RCT)−58%1.58 · 0.54–4.56death8/655/64 Ware (DB RCT)−294%3.94 · 0.45–34.29death4/651/64 Ware (DB RCT)−12%1.12 · 0.61–2.04progression17/6515/64 Ware (DB RCT)−42%1.42 · 0.65–3.09no recov.13/659/64

00.511.52+

Rotate screen for more detailsIncrease width for more details

← BI 764198
reduces riskBI 764198
increases risk →